6
Participants
Start Date
August 4, 2022
Primary Completion Date
October 31, 2023
Study Completion Date
February 29, 2024
Osimertinib
"Osimertinib is a Tyrosine Kinase Inhibitor (TKI). It is an irreversible inhibitor of Epidermal Growth Factor Receptors (EGFRs) harboring sensitising-mutations (EGFRm) and TKI-resistance mutation T790M.~The appropriate number of osimertinib tablets (80 mg or 40 mg if the dose is reduced due to toxicity) will be provided to patients to be self-administered at home."
Stereotactic Body Radiation Therapy (SBRT)
SBRT will be delivered using risk-adapted SBRT with a maximum of 5 SBRT fractions.
Universitätsspital Zürich USZ, Zurich
National Cancer Center, Goyang-si
Centro Integral Oncologíco Clara Campal (CIOCC) HM Hospitales, Madrid
IRCCS - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola
Instituto Europeo di Oncologia (IEO), Milan
AULSS2 Marca Trevigiana Treviso, Treviso
Leiden University Medical Center, Leiden
Medical University Gdansk, Gdansk
National University Hospital, Singapore
Severance Hospital, Yonsei University Health System, Sinchŏn-dong
Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona
Hospital Clínico de Valencia, Valencia
Sahlgrenska University Hospital, Gothenburg
Kantonsspital Aarau, Aarau
The Netherlands Cancer Institute Amsterdam, Amsterdam
Hospital General de Alicante, Alicante
Vall d'Hebron University Hospital, Barcelona
Karolinska Universitetssjukhuset Solna, Stockholm
Collaborators (1)
AstraZeneca
INDUSTRY
ETOP IBCSG Partners Foundation
NETWORK